Compare VRDN & CUBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRDN | CUBI |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.7B |
| IPO Year | N/A | 2012 |
| Metric | VRDN | CUBI |
|---|---|---|
| Price | $32.11 | $81.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $41.17 | ★ $84.14 |
| AVG Volume (30 Days) | ★ 1.2M | 271.4K |
| Earning Date | 02-26-2026 | 01-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.96 |
| Revenue | $70,789,000.00 | ★ $651,983,000.00 |
| Revenue This Year | $26,257.62 | $18.60 |
| Revenue Next Year | $4.54 | $7.66 |
| P/E Ratio | ★ N/A | $16.17 |
| Revenue Growth | ★ 23340.07 | N/A |
| 52 Week Low | $9.90 | $40.75 |
| 52 Week High | $34.29 | $80.96 |
| Indicator | VRDN | CUBI |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 66.11 |
| Support Level | $29.63 | $75.14 |
| Resistance Level | $34.29 | $79.78 |
| Average True Range (ATR) | 1.35 | 2.30 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 59.29 | 92.17 |
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.